- cafead   Jul 18, 2023 at 12:12: PM
via RNAi therapeutics made clinical headway in Alzheimer’s disease Monday, as Alnylam announced data from a Phase I study of ALN-APP showing the therapy reduced levels of an Alzheimer’s-linked protein by around two-thirds.
article source
article source